Results of Operations and Financial Condition. On August 3, 2026, Inspire Medical Systems, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2026. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Director — Michael H. Carrel: Appointment of Michael H. Carrel to the Board and various committees.

Director — Casey Tansey: Mr. Tansey decided to retire from the Board and not stand for re-election.

The filing appears to be a placeholder or introductory text and does not specify any actual management change.

Results of Operations and Financial Condition. On May 4, 2026, Inspire Medical Systems, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2026. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

of this Current Report on Form 8-K (and in the press release attached as Exhibit 99.1 hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

CFO — Matthew J. Osberg: The filing discloses the appointment of an external candidate as Chief Financial Officer, which is a significant management change but not a departure of a sitting executive.

Results of Operations and Financial Condition. On January 12, 2026, Inspire Medical Systems, Inc. (the “Company”) issued a press release announcing certain preliminary and unaudited results for the quarter and full year ended December 31, 2025. These preliminary financial results are based on the Company’s current estimate of its results for the year ended December 31, 2025, and remain subject to change based on the completion of closing and review procedures and the execution of the Company’…

Other Events. On November 6, 2025, Inspire Medical Systems, Inc. (“Inspire” or the “Company”) disclosed its expectation to release a significant portion of the valuation allowance on its U.S. deferred tax assets during the fourth quarter of fiscal 2025. The Company estimates that this release will result in an income tax benefit in the range of $90 million to $100 million for the year, which is expected to increase diluted earnings per share by approximately $3.00 to $3.30 for the same period…

Results of Operations and Financial Condition. On November 3, 2025, Inspire Medical Systems, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2025. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

CFO — Richard J. Buchholz: The CFO is resigning to pursue other opportunities, creating a vacancy in a critical executive role despite an orderly transition plan.

Other Events. On August 11, 2025, Inspire Medical Systems, Inc. (the “Company”) issued a press release announcing that its Board of Directors has authorized the repurchase of up to $200.0 million of the Company’s outstanding shares of common stock. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Executive Vice President — Randall A. Ban: The filing discloses a planned retirement of an Executive Vice President with a specific future effective date, indicating an orderly succession rather than a sudden loss.

Results of Operations and Financial Condition. On August 4, 2025, Inspire Medical Systems, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2025. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Results of Operations and Financial Condition. On May 5, 2025, Inspire Medical Systems, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2025. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Results of Operations and Financial Condition. On February 10, 2025, Inspire Medical Systems, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and full year ended December 31, 2024. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Results of Operations and Financial Condition. On January 13, 2025, Inspire Medical Systems, Inc. (the “Company”) issued a press release announcing certain preliminary and unaudited results for the quarter and full year ended December 31, 2024. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Other Events On November 8, 2024, Inspire Medical Systems, Inc. (the “Company”) entered into an accelerated share repurchase (“ASR”) transaction under an agreement (the “ASR Agreement”) with Goldman Sachs & Co. LLC (“GS&Co.”), to repurchase an aggregate of $75.0 million (the “Repurchase Price”) of shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”). The ASR transaction is being completed pursuant to a previously announced $150.0 million share repurchase progr…

Results of Operations and Financial Condition. On November 4, 2024, Inspire Medical Systems, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2024. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Other Events. On August 6, 2024, the Company announced that its Board of Directors has authorized the repurchase of up to $150.0 million of the Company’s outstanding shares of common stock. The full text of the press release is furnished as Exhibit 99.3 to this Current Report on Form 8-K and is incorporated herein by reference. The information in each of

Results of Operations and Financial Condition. On August 6, 2024, Inspire Medical Systems, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2024. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

of this Current Report on Form 8-K (“Form 8-K”) (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

COO — Philip J. Ebeling: The Chief Operating Officer is resigning to join a competitor, creating a leadership vacancy that requires a search.

Results of Operations and Financial Condition. On May 7, 2024, Inspire Medical Systems, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2024. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.